8-K: Xeris sets record 2025 revenue; guides 30%+ growth

Xeris Biopharma delivered record Q4 and full-year 2025 revenue, turned profitable, and guided 2026 revenue to $375–$390 million with higher investment in XP-8121 and Recorlev.

Summary

• Q4 2025 total revenue was $85.8 million (+42.8% YoY), led by Recorlev $45.3 million (+100.5%), Gvoke $24.6 million (+5.9%), and Keveyis $12.8 million (+15.1%).
• Full-year 2025 total revenue was $291.8 million (+43.7% YoY): Recorlev $139.3 million (+116.7%), Gvoke $94.1 million (+13.6%), Keveyis $47.6 million (-3.8%).
• Q4 net income was $11.1 million versus a net loss of $5.1 million in Q4 2024; full-year 2025 net income was $0.6 million versus a net loss of $54.8 million in 2024.
• Adjusted EBITDA was $25.1 million in Q4 2025 and $59.4 million for full-year 2025 (up from $8.3 million and $1.2 million in the prior-year periods).
• Full-year 2025 operating costs: COGS $42.6 million (+16%), R&D $31.2 million (+22%, driven by XP-8121), SG&A $182.4 million (+12%).
• Balance sheet at 12/31/2025: cash $111.0 million (up from $71.6 million), total debt ~$235.4 million (including $15.1 million current portion), stockholders’ equity turned positive at $13.7 million.
• Total shares outstanding were 172,431,290 as of February 27, 2026.
• 2026 guidance: total revenue $375–$390 million (midpoint ≈ +31% YoY), modest gross margin improvement, R&D up ≈ $25 million (XP-8121 Phase 3), SG&A up ≈ $45 million (Recorlev investments), Adjusted EBITDA to increase versus 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong update: record growth, first profitable year, and robust 2026 guidance, tempered by higher 2026 opex and a leveraged balance sheet.

Positives

• Record Q4 and full-year 2025 revenue ($85.8 million and $291.8 million, respectively), with strong product momentum.
• Recorlev net revenue more than doubled YoY to $139.3 million in 2025, highlighting robust patient demand.
• Turned profitable: Q4 net income of $11.1 million and full-year 2025 net income of $0.6 million versus a $54.8 million loss in 2024.
• Adjusted EBITDA expanded to $59.4 million in 2025 from $1.2 million in 2024, demonstrating improved operating leverage.
• Cash increased to $111.0 million at year-end 2025 and stockholders’ equity turned positive to $13.7 million, reflecting a stronger balance sheet.
• 2026 revenue guidance of $375–$390 million implies ~31% growth at the midpoint, alongside a planned increase in Adjusted EBITDA.

Negatives

• Keveyis revenue declined 3.8% in 2025 to $47.6 million due to unfavorable net pricing.
• Interest expense remained elevated at $29.1 million in 2025, contributing to $24.3 million in other expenses.
• Total debt is substantial at approximately $235.4 million (including current portion), limiting financial flexibility.
• Operating expenses set to rise meaningfully in 2026 (R&D +~$25 million; SG&A +~$45 million), which could pressure near-term profitability despite higher EBITDA.

Risks

• Need for financing to fund product development programs or commercialization efforts.
• Ability of products to achieve and maintain market acceptance in a competitive environment.
• Reliance on third-party suppliers, including single‑source suppliers, which could disrupt production.
• Dependence on third parties to conduct clinical trials, potentially affecting timelines and quality.
• Competition from existing and new drugs that could limit product uptake.
• Ability to protect intellectual property and proprietary technology.
• Accuracy of assumptions and estimates regarding future financial results and market opportunities.
• Macroeconomic and geopolitical conditions, including economic downturns, political unrest, trade disputes, changes in U.S. governmental priorities, tariffs or export controls, and market volatility.

Future Outlook

For 2026, management expects total revenue of $375–$390 million (midpoint ~31% growth), modest gross margin improvement from favorable product mix, approximately $25 million higher R&D tied to initiating XP-8121 Phase 3, approximately $45 million higher SG&A driven by Recorlev investments, and an increase in Adjusted EBITDA versus 2025.

Management Comments

• CEO: 2025 was transformational with record revenue growth and a shift to a self-funding, sustainable biopharma model; priorities in 2026 include rapid revenue growth, timely XP-8121 Phase 3 initiation, and disciplined capital deployment.
• CFO: The 2026 outlook calls for total revenue of $375–$390 million (30%+ growth at midpoint), further strengthening the balance sheet and financial flexibility for near- and long-term value creation.

Industry Context

StockSavvy.ai notes that sustained double-digit revenue growth and positive Adjusted EBITDA are above the typical trajectory for small- to mid-cap commercial-stage biopharmas. Emphasis on expanding Recorlev and advancing a Phase 3 endocrine asset (XP-8121) positions Xeris competitively among specialty pharma peers focused on rare endocrine and metabolic disorders.

Comparison to Industry Standards

• Compared with many small-cap commercial biopharmas that remain loss-making through scale-up, achieving positive net income and ~$59 million Adjusted EBITDA in 2025 is a stronger-than-average operating outcome.
• Revenue growth guidance (~31% midpoint for 2026) exceeds the mid-teens growth often seen across specialty pharma peers; peers with similar or higher growth profiles include select endocrine/metabolic players, though many rely on fewer assets.
• Debt load (~$235 million) is higher than some peers with similar revenue scale, suggesting a more leveraged balance sheet versus companies like Corcept Therapeutics and Amphastar, which often operate with lower net leverage.
• Pipeline advancement to Phase 3 (XP-8121 hypothyroidism) aligns with specialty peers pursuing lifecycle and platform-driven growth; success here would compare favorably with late-stage programs that drive a second growth wave.

Stakeholder Impact

• Shareholders: Positive inflection to profitability and strong 2026 growth outlook; equity turned positive, potentially improving valuation and capital access.
• Employees: Increased R&D and SG&A spending signal continued hiring and investment to support XP-8121 and Recorlev growth.
• Customers/Patients: Continued supply and access supported by higher production and commercial investments; expanding endocrine and metabolic treatment options.
• Suppliers/Partners: Ongoing reliance on third parties, including single-source suppliers, underscores the importance of supply continuity and quality.
• Creditors: Improved EBITDA and positive net income enhance credit profile, though leverage remains elevated.

Next Steps

• Initiate Phase 3 clinical trial for XP-8121 (once-weekly subcutaneous hypothyroidism therapy) in 2026.
• Invest in Recorlev commercial expansion, driving SG&A higher by approximately $45 million in 2026.
• Increase R&D spending by approximately $25 million in 2026 to support XP-8121 and pipeline.
• Host earnings conference call and webcast on March 2, 2026 at 8:30 a.m. ET; replay available on Investor Relations site.
• Participate in March and April 2026 investor conferences (Leerink, Barclays, Jefferies, Needham).

Key Dates

Recommendation

Record 2025 performance, transition to profitability, and 2026 revenue guidance implying ~31% growth with increasing Adjusted EBITDA support a constructive outlook. While leverage is high and opex will rise to fund growth and XP-8121 Phase 3, cash has strengthened, equity turned positive, and Recorlev momentum remains robust—collectively warranting a buy for investors comfortable with development and leverage risks.

Keywords

Xeris Biopharma, XERS, Recorlev, Gvoke, Keveyis, XP-8121, hypothyroidism, Cushing's syndrome, glucagon, primary periodic paralysis, 2026 guidance, Adjusted EBITDA, biopharma revenue, Phase 3 trial, XeriSol, XeriJect